Ocular Therapeutix Reports Q2 GAAP EPS and Revenue Beats
Ocular Therapeutix (NASDAQ: OCUL) reported second-quarter results for fiscal year 2026, with a GAAP earnings per share of -$0.35, which exceeded the expected loss by $0.04. The company also generated revenue of $13.48 million in Q2, surpassing estimates by $0.28 million and remaining flat compared to the same quarter in 2025. The total net revenue for the second quarter was reported at $13.5 million, consistent with the prior year's performance despite a slight increase of just 0.1% on an annual basis. The results highlight Ocular Therapeutix’s ability to outperform expectations amid stable market conditions and ongoing challenges in its business operations. The company continues to focus on managing costs while maintaining revenue stability as it navigates the competitive landscape.
Tickers: $OCUL
Topics: Earnings Financial Performance